Calreticulin arms NK cells against leukemia

ABSTRACT

Calreticulin (CALR) exposed on the surface of cancer cells succumbing to therapy delivers robust phagocytic signals that support the activation of adaptive anticancer immune responses. Recent data from our group demonstrate that spontaneous CARL exposure on leukemic blasts also supports innate anticancer immunity by natural killer (NK) cells via an indirect mechanism relying on myeloid CD11c⁺CD14⁺ cells.

KEYWORDS:

• Anticancer immunity
• CD80
• CCR7
• IL15
• immunogenic cell death
• MHC Class II
• type I IFN

Disclosures

JF and RS are supported by Sotio, Prague, Czech Republic. LG provides remunerated consulting to OmniSEQ (Buffalo, NY, USA), Astra Zeneca (Gaithersburg, MD, USA), Inzen (New York, NY, USA) and the Luke Heller TECPR2 Foundation (Boston, MA, USA), and he is member of the Scientific Advisory Committee of OmniSEQ (Buffalo, NY, USA).